| Biomarker ID | 1885 |
| PMID | 30623593 |
| Year | 2018 |
| Biomarker | SCOâ€spondin; Complement component C7;Isoform 2 of Ankyrin repeat and SOCS box protein 18; Gelsolin; Serum amyloid Pâ€component; g heavy chain Vâ€I region V35; Complement C1q subcomponent subunit C; Complement component C8 alpha chain; Isoform 2 of Filamin A; Inter-alpha trypsin inhibitor heavy chain H2; |
| Biomarker Basis | Concentration Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa (Keratin, type II cytoskeletal 2 epidermal (64 fold); Serum amyloid Pâ€component (39 fold) ;Keratin, type II cytoskeletal 1 (13 fod) ; Keratin, type I cytoskeletal 9 (12 fold) ; Isoform 2 of Filamin A (2.6 fold) ; Isoform 3 of Vitamin Dâ€binding protein (2.4 fold); Ig kappa chain Vâ€II region Cum (2.4 fold) ; Isoform 2 of Eukaryotic translation initiation 1.8 factor 2â€alpha kinase 4 (1.8 fold) ; Ig alphaâ€1 chain C region (1.7 fold) ; Afamin (1.5 fold); |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer in Caucasian American Men Vs Normal Caucasian American Men |
| Type of Biomarker | Diagnostic |
| Cohort | Serum samples from African American and Caucasian PCa patients and matched healthy donors were collected after patients’ consents |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | mass spectrometry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |